Answer
Breastfeeding should be discontinued during treatment with Veletri (epoprostenol sodium), because it is unknown whether epoprostenol or its metabolites are excreted in human milk and a risk to the breastfeeding child cannot be excluded.
Sources for this answer
- Veletri 1.5mg, Powder for Solution for InfusionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 14Document updated
Sources checked